To determine if human cancers that have ESCO2 deficiencies also have higher MR rates, we analyzed TCGA data to define all LOH loci that maintained a 2N copy number (Fig 6C), this would exclude regional deletions or whole chromosome deletion, as well as amplifications. This evidence concerns the gene ESCO2 and cancer.